Coronavirus: Pfizer, BioNTech apply for EU approval of vaccine

EU chief Ursula von der Leyen says expediting 10 million doses will give Member States "room to maneuver," after several EU countries halted the use of the AstraZeneca shot.

Brussels says its third contract with the US-German vaccine consortium is the world's largest supply deal so far to stem the coronavirus' spread.

The FDA is expected to approve the BioNTech-Pfizer COVID-19 vaccine for adolescents between the ages of 12 and 15 next week, according to media reports. DW has the latest.

The German-developed coronavirus vaccine has become the first to get the go ahead for use among children aged 12 and up.

The CDC has given a green light to using the BioNTech-Pfizer vaccine in children aged 12 to 15. Meanwhile, Cuba has started inoculating its citizens using two locally produced vaccines. Follow DW for the latest.

President Joe Biden is expected to make the announcement before the G7 summit kicks off. The donation comes as the US attempts to reclaim its role as a global leader after four years of isolationism.

The US Centers for Disease Control and prevention have confirmed that myocarditis and pericarditis can occur after mRNA vaccination in young people. But the cases are rare. Medical experts still recommend the shots.

BioNTech and Pfizer said an extra dose of their jab could boost immunity against the coronavirus delta variant. South Korea raised pandemic restrictions as cases hit the "maximum crisis level." Follow DW for the latest.

The Biovac Institute reached a deal with Pfizer to prepare and deliver vaccine doses for the continent. It comes amid an increase of cases in Africa, where just 2% of the population have received a first dose.

Researchers say two shots of either BioNTech-Pfizer or AstraZeneca vaccines are highly effective against variants. Elsewhere, China has declined to follow an investigation into the virus's origins. Follow DW for more.

After developing a coronavirus vaccine in record time, the German pharmaceutical company aims to start trialing a malaria shot next year using the same breakthrough mRNA technology.

Vaccines from both drugmakers have been approved in the EU for children from 12 to 17 years of age. Elsewhere, Australia continues its battle against the delta variant. Follow DW for the latest.